Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract

This study has been completed.
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center Identifier:
First received: May 5, 2009
Last updated: May 12, 2014
Last verified: May 2014
The purpose of this trial is to determine whether or not Cialis (tadalafil) administered to head and neck squamous cell cancer patients augments immune response.

Condition Intervention Phase
Head and Neck Squamous Cell Carcinoma
Drug: Tadalafil
Other: Placebo Pill
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract

Resource links provided by NLM:

Further study details as provided by Sidney Kimmel Comprehensive Cancer Center:

Primary Outcome Measures:
  • Increase in immune response after tadalafil administration [ Time Frame: 10-14 days ]

Enrollment: 40
Study Start Date: January 2009
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Other: Placebo Pill
Experimental: Drug
Tadalafil 20 mg once per day
Drug: Tadalafil
20 mg once daily for 10 - 14 days
Other Name: Cialis


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically confirmed, previously untreated invasive head and neck squamous cell carcinoma OR histologically confirmed not yet treated recurrent head and neck squamous cell carcinoma (must be at least 3 months after diagnosis and completion of treatment for primary disease or last recurrence).
  2. Disease location amenable to biopsy in outpatient clinical setting or operative biopsy within routine accepted schedule and practice of clinical care
  3. No medical contraindication to biopsy of target lesion.
  4. ECOG performance status 0-1
  5. Required laboratory data (to be obtained within 4 weeks of initiation):

    • Platelets > 75,000/mm³
    • Calculated Creatinine Clearance (CRCL)> 60 mL/min iii. Total serum bilirubin < 1.5 mg/dL.
    • No intercurrent illness likely to prevent protocol therapy or surgical resection
  6. Patients with a history of a curatively treated malignancy must be disease-free and have a survival prognosis that exceeds five years.
  7. Female patients must not be pregnant or breast feeding. A negative pregnancy test is required within 14 days of randomization for all women of childbearing potential.
  8. Willingness and ability to give signed written informed consent.

Exclusion Criteria:

  1. Known severe hypersensitivity to tadalafil or any of the excipients of this product
  2. Patients who have a concurrent malignancy or a history of previous malignancy treated with curative therapy within the last 3 months (other than squamous/basal cell cancer of the skin or cervical cancer) who have a survival prognosis of < 5 years.
  3. Treatment with a non-approved or investigational drug within 30 days before day 1 of trial treatment.
  4. Incomplete healing from previous oncologic or other major surgery.
  5. Pregnancy or breast feeding (women of childbearing potential).
  6. As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease).
  7. Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the trial.
  8. Current therapy with ketoconazole or oral antifungal therapy.
  9. History of significant hypotensive episode requiring hospitalization.
  10. A history of acute myocardial infarction within prior 3 months, uncontrolled angina,
  11. Uncontrolled arrhythmia, or uncontrolled congestive heart failure
  12. Age < 18
  13. History of any of the following cardiac conditions:

    • Angina requiring treatment with long-acting nitrates.
    • Angina requiring treatment with short-acting nitrates within 90 days of planned tadalafil administration.
    • Unstable angina within 90 days of visit 1 (Braunwald 1989).
    • Positive cardiac stress test without documented evidence of subsequent, effective cardiac intervention.
  14. History of any of the following coronary conditions within 90 days of planned tadalafil administration:

    • Myocardial Infarction.
    • Coronary artery bypass graft surgery.
    • Percutaneous coronary intervention (for example, angioplasty or stent placement).
    • Any evidence of heart disease (NYHA≥Class III as defined in Protocol Attachment LVHG.3) within 6 months of planned tadalafil administration
  15. Current treatment with nitrates.
  16. Current systemic treatment with a potent cytochrome P450 3A4 (CYP3A4) inhibitor such as ketoconazole or ritonavir.
  17. Received treatment within the last 30 days with a drug or device that has not received regulatory approval for any indication at the time of Visit 1.
  18. Prior chronic immune suppressive state (AIDS, immunosuppressive therapy).
  19. History of hypotension and/or blindness during prior treatment with Tadalafil or other PDE-5 inhibitors.
  20. prior history of non-arterial ischemic optic retinopathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00894413

United States, Maryland
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21205
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center
National Institutes of Health (NIH)
  More Information

Responsible Party: Sidney Kimmel Comprehensive Cancer Center Identifier: NCT00894413     History of Changes
Other Study ID Numbers: J0813, NA_00012749
1R21CA135635-01 ( US NIH Grant/Contract Award Number )
Study First Received: May 5, 2009
Last Updated: May 12, 2014

Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Neoplasms by Site
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents processed this record on April 28, 2017